Antibacterial activity of salicylanilide 4-(trifluoromethyl)benzoates

Molecules

Volumn 18, Issue 4, 2013, Pages 3674-3688

  Krátký, Martin ^a   Vinšová, Jarmila ^a   Novotná, Eva ^a   Mandíková, Jana ^a   Trejtnar, František ^a   Stolaříková, Jiřina ^b  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b Zdravotniho ustavu se sidlem v Ostrave   (Czech Republic)

Author keywords

4 (trifluoromethyl)benzoic acid ester; Antibacterial activity; Antimycobacterial activity; Cytotoxicity; Isocitrate lyase inhibitor; Multidrug resistant tuberculosis; Salicylanilide ester

Indexed keywords

3 NITROPROPIONIC ACID; 3-NITROPROPIONIC ACID; ANTIINFECTIVE AGENT; BENZOIC ACID DERIVATIVE; ISOCITRATE LYASE; NITRO DERIVATIVE; PROPIONIC ACID DERIVATIVE; SALICYLANILIDE; SALICYLANILIDE DERIVATIVE;

ARTICLE; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TEST; MYCOBACTERIUM AVIUM; MYCOBACTERIUM KANSASII; MYCOBACTERIUM TUBERCULOSIS;

ANTI-BACTERIAL AGENTS; BENZOATES; ISOCITRATE LYASE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM AVIUM; MYCOBACTERIUM KANSASII; MYCOBACTERIUM TUBERCULOSIS; NITRO COMPOUNDS; PROPIONATES; SALICYLANILIDES;

EID: 84876769979     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules18043674     Document Type: Article

References (31)

1. WHO. 2011/2012 Tuberculosis Global Facts. Available online: http://www.who.int/tb/ publications/2011/factsheet-tb-2011.pdf (accessed on 12 December 2012).
2. Caminero, J.A. Extensively drug-resistant tuberculosis: Is its definition correct? Eur. Respir. J. 2008, 32, 1413-1415.
3. McKinney, J.D.; Bentrup, K.H.; Munoz-Elias, E.J.; Miczak, A.; Chen, B.; Chan, W.T.; Swenson, D.; Sacchettini, J.C.; Jacobs, W.R.; Russell, D.G. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 2000, 406, 735-738.
4. Krátký, M.; Vinšová, J.; Novotná, E.; Mandíková, J.; Wsól, V.; Trejtnar, F.; Ulmann, V.; Stolaříková, J.; Fernandes, S.; Bhat, S.; Liu, J.O. Salicylanilide derivatives block Mycobacterium tuberculosis through inhibition of isocitrate lyase and methionine aminopeptidase. Tuberculosis 2012, 92, 434-439.
5. Krátký, M.; Vinšová, J. Advances in mycobacterial isocitrate lyase targeting and inhibitors. Curr. Med. Chem. 2012, 19, 6126-6137.
6. Cabrera, C.E.; Gómez, R.F.; Zuñiga, A.E.; Corral, R.H.; López, B.; Chávez, M. Epidemiology of nosocomial bacteria resistant to antimicrobials. Colomb. Med. 2011, 42, 117-125.
7. Scientific Blueprint for Tuberculosis Drug Development. Available online: http://www.tballiance.org/ downloads/publications/TBA-Scientific-Blueprint.pdf (accessed on 12 December 2012).
8. Krátký, M.; Vinšová, J. Salicylanilide ester prodrugs as potential antimicrobial agents - A review. Curr. Pharm. Des. 2011, 17, 3494-3505.
9. Krátký, M.; Vinšová, J.; Buchta, V.; Horvati, K.; Bösze, S.; Stolaříková, J. New amino acid esters of salicylanilides active against MDR-TB and other microbes. Eur. J. Med. Chem. 2010, 45, 6106-6113.
10. Krátký, M.; Vinšová, J.; Rodriguez, N.G.; Stolaříková, J. Antimycobacterial activity of salicylanilide benzenesulfonates. Molecules 2012, 17, 492-503.
11. Krátký, M.; Vinšová, J.; Buchta, V. In vitro antibacterial and antifungal activity of salicylanilide benzoates. ScientificWorldJournal 2012, 12, doi:10.1100/2012/290628.
12. Krátký, M.; Vinšová, J.; Buchta, V. In vitro antibacterial and antifungal activity of salicylanilide pyrazine-2-carboxylates. Med. Chem. 2012, 8, 732-741.
13. Krátký, M.; Vinšová, J.; Stolař íková, J. Antimycobacterial assessment of salicylanilide benzoates including multidrug-resistant tuberculosis strains. Molecules 2012, 17, 12812-12820.
14. Cheng, T.J.R.; Wu, Y.T.; Yang, S.T.; Lo, K.H.; Chen, S.K.; Chen, Y.H.; Huang, W.I.; Yuan, C.H.; Guo, C.W.; Huang, L.Y.; et al. High-throughput identification of antibacterials against methicillin-resistant Staphylococcus aureus (MRSA) and the transglycosylase. Bioorg. Med. Chem. 2010, 18, 8512-8529.
15. Garner, A.L.; Gloeckner, C.; Tricoche, N.; Zakhari, J.S.; Samje, M.; Cho-Ngwa, F.; Lustigman, S.; Janda, K.D. Design, synthesis, and biological activities of closantel analogues: Structural promiscuity and its impact on Onchocerca volvulus. J. Med. Chem. 2011, 54, 3963-3972.
16. Fomovska, A.; Wood, R.D.; Mui, E.; Dubey, J.P.; Ferreira, L.R.; Hickman, M.R.; Lee, P.J.; Leed, S.E.; Auschwitz, J.M.; Welsh, W.J.; et al. Salicylanilide inhibitors of Toxoplasma gondii. J. Med. Chem. 2012, 55, 8375-8391.
17. Ding, N.; Zhang, W.; Xiao, H.L.; Wang, P.; Li, Y.X. Synthesis and biological evaluation of a series of novel salicylanilides as inhibitors of EGFR protein tyrosine kinases. Chin. Chem. Lett. 2012, 23, 529-532.
18. Steffen, J.D.; Coyle, D.L.; Damodaran, K.; Beroza, P.; Jacobson, M.K. Discovery and structureactivity relationships of modified salicylanilides as cell permeable inhibitors of poly(ADP-ribose) glycohydrolase (PARG). J. Med. Chem. 2011, 54, 5403-5413.
19. Zuo, M.; Zheng, Y.W.; Lu, S.M.; Li, Y.; Zhang, S.Q. Synthesis and biological evaluation of N-aryl salicylamides with a hydroxamic acid moiety at 5-position as novel HDAC-EGFR dual inhibitors. Bioorg. Med. Chem. 2012, 20, 4405-4412.
20. Zhu, Z.W.; Shi, L.; Ruan, X.M.; Yang, Y.; Li, H.Q.; Xu, S.P.; Zhu, H.L. Synthesis and antiproliferative activities against Hep-G2 of salicylanide derivatives: potent inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase. J. Enzym. Inhib. Med. Chem. 2011, 26, 37-45.
21. Liu, X.H.; Lv, P.C.; Li, B.; Zhu, H.L.; Song, B.A. Synthesis, structure, and antibacterial activity of novel 5-arylpyrazole derivatives. Aust. J. Chem. 2008, 61, 223-230.
22. Krátký, M.; Vinšová, J. Antifungal activity of salicylanilides and their esters with 4-(trifluoromethyl)benzoic acid. Molecules 2012, 17, 9426-9442.
23. Waisser, K.; Bureš, O.; Holý, P.; Kuneš, J.; Oswald, R.; Jirásková, L.; Pour, M.; Klimešová, V.; Kubicová, L.; Kaustová, J. Relationship between the structure and antimycobacterial activity of substituted salicylanilides. Arch. Pharm. Pharm. Med. Chem. 2003, 336, 53-71.
24. Imramovský, A.; Vinšová, J.; Férriz, J.M.; Doležal, R.; Jampílek, J.; Kaustová, J.; Kunc, F. New antituberculotics originated from salicylanilides with promising in vitro activity against atypical mycobacterial strains. Bioorg. Med. Chem. 2009, 17, 3572-3579.
25. Férriz, J.M.; Vávrová, K.; Kunc, F.; Imramovský, A.; Stolaříková, J.; Vavříková, E.; Vinšová, J. Salicylanilide carbamates: Antitubercular agents active against multidrug-resistant Mycobacterium tuberculosis strains. Bioorg. Med. Chem. 2010, 18, 1054-1061.
26. Liu, X.H.; Song, B.A.; Bhadury, P.S.; Zhu, H.L.; Cui, P.; Hou, K.K.; Xu, H.L. Novel 5-(3- (substituted)-4,5-dihydroisoxazol-5-yl)-2-methoxyphenyl derivatives: Synthesis and anticancer activity. Aust. J. Chem. 2008, 61, 864-869.
27. Wada, K.; Ohkoshi, E.; Morris-Natschke, S.L.; Bastow, K.F.; Lee, K.H. Cytotoxic esterified diterpenoid alkaloid derivatives with increased selectivity against a drug-resistant cancer cell line. Bioorg. Med. Chem. Lett. 2012, 22, 249-252.
28. Deng, W.; Guo, Z.; Guo, Y.; Feng, Z.; Jiang, Y.; Chu, F. Acryloylamino-salicylanilides as EGFR PTK inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 469-472.
29. Liechti, C.; Séquin, U.; Bold, G.; Furet, P.; Meyer, T.; Traxler P. Salicylanilides as inhibitors of the protein tyrosine kinase epidermal growth factor receptor. Eur. J. Med. Chem. 2004, 39, 11-26.
30. Bradford, M.M. Rapid and sensitive method for quantitation of microgram quantities of protein utilizing principle of protein-dye binding. Anal. Biochem. 1976, 72, 248-254.
31. Dixon, G.H.; Kornberg, H.L. Assay methods for key enzymes of the glyoxylate cycle. Biochem. J. 1959, 72, P3.